November 6, 2006Open Access

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

ACAsher Chanan‐KhanWinnMed KMKena C. MillerTakeda (United States)LMLaurie MusialRoswell Park Comprehensive Cancer Center

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Lenalidomide is clinically active in patients with relapsed or refractory B-CLL. These findings are encouraging and warrant further investigation of this agent in the treatment of this disorder.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Chanan‐Khan et al. (Mon,) studied this question.

synapsesocial.com/papers/69dc99417873f5f05b1336d8 https://doi.org/https://doi.org/10.1200/jco.2005.05.0401

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)2005 · 105 citations
2Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?2001 · 340 citations
3Impairments in immune cell function in B cell chronic lymphocytic leukemia.1998 · 105 citations
4Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells2005 · 298 citations
5Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction [see comments]1991 · 395 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo